Usefulness of SS18-SSX antibody as a diagnostic marker for pulmonary metastatic synovial sarcoma

doi:10.21203/rs.3.rs-386235/v1

PDF

Research

Usefulness of SS18-SSX antibody as a diagnostic marker for pulmonary metastatic synovial sarcoma

https://doi.org/10.21203/rs.3.rs-386235/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

Background

The novel SS18-SSX fusion-specific antibody is reported to have high sensitivity and specificity for the diagnosis of primary synovial sarcoma (SS), which often metastasizes to the lung. Thus far, no study has validated the diagnostic efficacy of SS18-SSX antibody for pulmonary metastatic SS, and this is the first study to report these findings. We aimed to investigate the usefulness of the SS18-SSX antibody in the diagnosis of pulmonary metastatic SS.

Methods

We evaluated the immunohistochemistry of SS18-SSX fusion-specific antibody (E9X9V) in 10 pulmonary metastatic SS cases and the corresponding five primary sites (four limbs and one mediastinum) in five patients (SS diagnosis of was already confirmed by fluorescence in-situ hybridization in the metastatic and primary sites), and in 93 clinical and histologic mimics including 49 non-SS, pulmonary metastatic sarcomas, 39 primary lung cancers, and five intrathoracic solitary fibrotic tumors. All specimens were surgically resected at Shinshu University Hospital during 2001–2019. For primary and metastatic SS, we also evaluated SS18-SSX immunohistochemistry in needle biopsy and touch imprint cytology specimens from the primary site.

Results

SS18-SSX had stained diffusely strong in all 10 pulmonary metastatic SS cases and the corresponding five primary sites without staining of SS18-SSX in all 93 clinical and histologic mimics (100% sensitivity and 100% specificity). SS18-SSX had sufficiently stained in the biopsy and cytology specimens.

Conclusions

Immunohistochemistry of the SS18-SSX fusion-specific antibody is useful for the differential diagnosis of pulmonary metastatic SS in clinical practice. This simple and reliable method can replace traditional genomic tests.

Laboratory Diagnostics

Pathology

Cardiothoracic Surgery

synovial sarcoma

SS18-SSX antibody

immunohistochemistry

pulmonary metastasis

Synovial sarcoma (SS) is a malignant mesenchymal neoplasm with varying epithelial differentiation, and it accounts for 5–10% of all soft tissue sarcomas [1–4]. SS frequently occurs in the limbs and occasionally in the chest cavity. Approximately 50% of SS patients experience metastasis commonly to the lungs and pleura [3, 5]. In patients with resectable pulmonary metastases of SS, the mainstay of treatment is pulmonary metastasectomy, which is reported to show good prognosis [6–8]. Several studies reported that repeated pulmonary metastasectomies would be a feasible strategy for select patients with metastatic SS [9, 10]. Therefore, thoracic surgeons would frequently encounter cases of pulmonary metastatic SS in clinical practice.

A diagnosis of SS is made depending on the presence of the hallmark t(X;18)(p11;q11) translocation, which is not found in other neoplasms [4, 11]. This recurrent translocation results in the fusion of the SS18 gene on chromosome 18 with one of the several SSX genes on chromosome X (SSX1 in two-thirds of SS, SSX2 in one-third, and SSX4 rarely), which create SS18-SSX fusion oncogenes in > 95% of cases [4, 11, 12]. Histologically, SS is divided into two major subtypes (biphasic type and monophasic spindle cell type) and other rarer subtypes (monophasic epithelial, poorly differentiated, calcifying/ossifying, and myxoid types) [3, 4]. Owing to the varying histological combination of epithelioid and spindle cells, the differential diagnosis of SS widely ranges from non-SS bone and soft tissue sarcomas to various types of carcinoma. Therefore, making a definitive diagnosis of SS based only on histological findings is difficult, and genetic confirmation of the SS18-SSX fusion by fluorescence in situ hybridization (FISH) or reverse transcriptase-polymerase chain reaction (RT-PCR) has been the gold standard for the diagnosis of SS [3, 4]. However, these tests are not widely available because of their high cost and time-consuming process [13].

In patients with pulmonary metastatic SS, clinical course, radiologic features, and histologic findings are widely variable, resulting in difficulties in the differential diagnosis of SS from clinical and histologic mimics such as primary lung cancer and other bone/soft tissue sarcomas [3, 14, 15]. Particularly in cases of late and solitary pulmonary metastatic SS, the differential diagnosis would be difficult but clinically important. Therefore, a clinically useful and pathologically accurate test for the diagnosis of metastatic SS is warranted.

Recently, Baranov et al. proposed a novel diagnostic test for SS using immunohistochemistry (IHC) of the SSX-SS18 fusion-specific antibody, with high sensitivity (95%) and specificity (100%) for the diagnosis of primary SS [4]. However, it has not been clarified whether SS18-SSX IHC can be used as a marker to diagnose pulmonary metastatic SS, particularly in the differential diagnosis from clinical and histologic mimics such as primary lung cancers and pulmonary metastatic non-SS sarcomas.

The present study aimed to evaluate the usefulness of SS18-SSX IHC in the diagnosis of pulmonary metastatic SS and the diagnosis of the rare mediastinum-originated SS and the potential utility of biopsy and/or cytology specimens for the IHC test.

Study cohort and design

We retrieved the details of surgically resected patients from the Pathology Department of Shinshu University Hospital during 2001–2019. The whole slides of the tumor were available for 10 pulmonary metastatic SS and the corresponding five primary sites (four in the limbs and one mediastinum) in 5 patients and in 93 clinical and histologic mimics, including 49 pulmonary metastatic bone and soft tissue sarcomas other than SS (osteosarcoma, chondrosarcoma, liposarcoma, malignant fibrous histiocytoma, Ewing’s sarcoma, leiomyosarcoma, fibrosarcoma, and undifferentiated sarcoma), 39 primary lung cancers (adenocarcinoma, squamous cell carcinoma, small cell lung cancer, large cell lung cancer, pleomorphic cell carcinoma, and carcinoid), and 5 intrathoracic solitary fibrotic tumors. All SS patients underwent surgical resection of the primary origin and were diagnosed with SS by SS18 break-apart FISH to detect the SS18-SSX fusion gene. In metastatic SS specimens, two metastatic sites were selected from each patient, and a total of 10 specimens were stained. SS and other bone and soft tissue sarcomas were consecutive cases, including repeated pulmonary metastasectomies. Patients with SFT and primary lung cancer were randomly selected from our database. This study was approved by the Shinshu University Research Ethics Committee (No. 4870).

Immunohistochemical staining

IHC staining was performed by manual methods. Specimens of whole tumors (SS, other bone soft tissue sarcoma, primary lung cancer, and solitary fibrotic tumor [SFT]) were paraffin-embedded and cut into 4-µm-thick sections. They were deparaffinized with ethanol and xylene, and endogenous peroxidase activity was blocked using methanol and 30% H₂O₂ solution for 30 min at room temperature. Protein blocking was performed using 1% bovine serum albumin [BSA]/phosphate-buffered saline [PBS] for 1 h at room temperature. The sections were incubated overnight at 4°C with primary antibody against human SS18-SSX (clone E9X9V, 1:1000, Cell Signaling Technology, Danvers, MA, USA). The sections were washed in PBS three times and probed with an anti-rabbit IgG labeled with Histofine Simple Stain MAX-PO (Nichirei, Tokyo, Japan) for 1 h at room temperature. They were washed three times in PBS, and the immune complex was visualized using Histofine Simple Stain 3,3′-diaminobenzidine (Nichirei, Tokyo, Japan). After washing in water, the sections were counterstained with hematoxylin.

Immunostaining of intraoperative sealed cytology was performed in almost the same manner. The tumor was directly smeared onto the slide grass and then fixed with 99.5% ethanol. The subsequent immunostaining steps were the same.

Immunoactivity was reviewed by one pathologist (UT) and one thoracic surgeon (MK).

Characteristics of patients with synovial sarcoma

The characteristics of patients with SS are presented in Table 1. All SS of primary origin and pulmonary metastasis had already been diagnosed using SS18 break-apart FISH. The age at the identification of the primary tumor as SS was considered for each patient. In all 5 patients with SS, at least two metachronous metastasectomies were performed. The duration between the resection of primary sites and pulmonary metastasectomies ranged from 28 to 108 months. Cases 1, 3, 4, and 5 were monophasic spindle cell types, and Case 2 was biphasic type.

Table 1

Characteristics of the five patients with synovial sarcoma who underwent pulmonary metastasectomy.
Case no.	Age, years	Sex	Primary	State	Type	1st	2nd	3rd	4th	5th
1	63	F	Ankle	Dead	Monophasic	Left wedge resection (1)	Right wedge resection (2)	Left wedge resection (1)
						39 months	59 months	61 months
2	28	M	Mediastinum	Alive	Biphasic	Right lower lobectomy (1)	Left wedge resection + chest wall resection
						108 months	177 months
3	33	M	Forearm	Alive	Monophasic	Right basal segmentectomy (1)	Left wedge resection (1)	Left basal segmentectomy (1)	Left wedge resection (1)
						48 months	63 months	82 months	100 months
4	51	M	Knee	Alive	Monophasic	Right wedge resection (2)	Left wedge resection (2)	Right wedge resection (1)	Left wedge resection (1)	Right wedge resection (1)
						28 months	59 months	76 months	97 months	108 months
5	30	M	Forearm	Alive	Monophasic	Right wedge resection (3)	Left wedge resection (2)	Right wedge resection (2)	Left wedge resection (3)
						32 months	34 months	68 months	107 months
The age at which the primary tumor was identified as SS was considered for each patient. The months listed below the operative procedure indicates the duration since the identification of the primary origin. The number in parentheses next to the surgical procedure indicates the number of resected tumors.

In Case 1, a 63-year-old woman with primary SS in the left ankle underwent pulmonary metastasectomy three times (left-sided wedge resection ×1 at 39 months after primary surgery followed by right-sided wedge resection ×2 at 59 months, and left-sided wedge resection ×1 at 61 months). The patient finally developed right-sided pleural dissemination and died of SS. IHC of SS18-SSX for pulmonary metastases was obtained from the first and second metastasectomy specimens. Figure 1A shows the computed tomographic findings of solitary pulmonary metastasis in the left lower lobe before the initial left wedge resection in this case.

In Case 2, a 28-year-old man had primary SS in the mediastinum. The large mass (60×60×40 mm) was protruding from the left side chest cavity (Fig. 2A, 2B), which was resected with combined pericardial resection by median sternotomy. The patients underwent metastasectomy twice (right lower lobectomy at 108 months after the primary surgery followed by left-sided chest wall resection with combined pulmonary wedge resection at 177 months). In this case, the definitive diagnosis of SS was not reached until the initial metastasectomy, which was 108 months after the primary surgery when SS was finally diagnosed through comprehensive pathology workups including SS18 break-apart FISH for primary and metastatic sites. Figure 2C shows FISH for SS18 rearrangement in the primary tissue, demonstrating a disconnected SS18 gene. No evidence of recurrence was observed 17 months after the last pulmonary metastasectomy.

Figure 2Computed tomography (CT) scan showing the results of fluorescence in situ hybridization for SS18 rearrangement and the results of immunostaining of SS18-SSX antibody in Case 2. (A)(B) The chest CT scan shows a mediastinal mass of size 60×60×40 mm. (C) Image showing the results of fluorescence in situ hybridization for SS18 rearrangement. A disconnected SS18 gene can be seen. (D) The SS18-SSX fusion-specific antibody (E9X9V) is positive.</fig>

In Case 3, a 33-year-old man with primary SS in the left forearm underwent pulmonary metastasectomy four times (right-sided basal segmentectomy at 48 months after the primary surgery followed by left-sided wedge resection ×1 at 63 months, left-sided basal segmentectomy at 83 months, and left-sided wedge resection ×1) and subsequent radiation therapy for right-sided pulmonary metastasis. Figure 1B shows the computed tomographic findings of the solitary pulmonary metastasis in the left lower lobe before left basal segmentectomy. IHC of SS18-SSX for pulmonary metastases was obtained from the first and second metastasectomy specimens. No evidence of recurrence was observed 2 months after the last pulmonary metastasectomy.

In Case 4, a 51-year-old man had the primary origin as the left knee. He underwent pulmonary metastasectomy five times (right-sided wedge resection ×2, left-sided wedge resection ×2, right-sided wedge resection ×1, left-sided wedge resection ×1 and right-sided wedge resection ×1). The patient was followed up without any treatment. IHC of SS18-SSX for pulmonary metastases was obtained from the third and fourth metastasectomy specimens. No evidence of recurrence was observed 10 months after the last pulmonary metastasectomy.

In Case 5, a 30-year-old man had the primary origin as the right forearm. He underwent pulmonary metastasectomies four times (right-sided wedge resection ×3, left-sided wedge resection ×2, right-sided wedge resection ×2 and left-sided wedge resection ×3). IHC of SS18-SSX for pulmonary metastases was obtained from the second and third metastasectomy specimens. He had recurrence and was undergoing chemotherapy.

IHC

Figure 3 shows the histologic findings of SS18-SSX IHC and hematoxylin and eosin of 10 pulmonary metastatic SS and 5 corresponding primary sites from 5 patients with SS. The SS18-SSX fusion-specific antibody was positive with diffusely strong staining in all 10 metastatic SS samples. All five primary SS tumors were stained similarly to the corresponding metastatic SS. However, no staining of SS18-SSX was observed in the 93 clinical and histologic mimics (49 other bone and soft tissue sarcomas, 39 primary lung cancers, and 5 SFTs). Figure 4 shows the histologic findings of SS18-SSX IHC of 15 representative cases from 93 clinical and histological mimics. A summary of the IHC results is presented in Table 2.

Table 2

Summary of the results of IHC staining for SS18-SSX antibody.
	Number	SS18-SSX-positive ratio
Synovial sarcoma (metastasis)	10	100%
Synovial sarcoma (primary)	5	100%
Non-SS pulmonary metastatic tumors
Osteosarcoma	8	0%
Chondrosarcoma	7	0%
Liposarcoma	5	0%
Malignant fibrous histiocytoma	9	0%
Ewing’s sarcoma	4	0%
Leiomyosarcoma	9	0%
Fibrosarcoma	3	0%
Undifferentiated sarcoma	4	0%
Primary lung cancer
Adenocarcinoma	9	0%
Squamous cell carcinoma	5	0%
Small cell lung cancer	4	0%
Large cell lung cancer	5	0%
Pleomorphic carcinoma	8	0%
Carcinoid	8	0%
Solitary fibrous tumor	5	0%
IHC: immunohistochemistry; SS: synovial sarcoma

Figure 5A shows the histologic finding of SS18-SSX IHC of a percutaneous needle biopsy specimen from the primary right forearm tumor in Case 5, demonstrating diffuse strong staining of SS18-SSX antibody similar to the surgically resected specimen (Fig. 3T). Figure 5B shows the cytological findings of SS18-SSX IHC of intraoperative touch imprint cytology specimen from the pulmonary metastatic site, demonstrating strong staining of the SS18-SSX antibody.

Figure 5Findings of immunostaining of SS18-SSX in the synovial sarcoma obtained by percutaneous biopsy in Case 5 (A) and intraoperative sealed cytology in Case 3 (B). The image shows strong diffuse nuclear staining.</fig>

In this study, we demonstrated the usefulness of the IHC of SS18-SSX fusion-specific antibody for the differential diagnosis of pulmonary metastatic SS from clinical and histological mimics. The significant findings of this study are as follows: 1) this is the first study to validate the diagnostic performance of SS18-SSX IHC for the diagnosis of pulmonary metastatic SS; 2) we examined SS18-SSX IHC in clinical and histologic mimics of pulmonary metastatic SS, including various types of primary lung cancers and pulmonary metastatic non-SS sarcomas; 3) the sensitivity and specificity for the diagnosis of pulmonary metastatic SS were high (both 100%); 4) positive SS18-SSX IHC was seen in the biopsy and cytology specimens, suggesting the usefulness of the test in clinical practice; 5) positive SS18-SSX IHC in a rare case of mediastinum-originated SS suggested a potential routine use of the test for the differential diagnosis of intrathoracic indeterminate sarcomas; and 6) the simple and widely prevalent IHC technique for the test with a high diagnostic performance could replace traditional genomic tests such as FISH or RT-PCR.

The standard test for the diagnosis of SS has been genomic tests to detect the SS18-SSX gene fusion by FISH or RT-PCR [13], which have reported to be highly specific tests. However, several studies suggested the relatively low sensitivity (83–94%) of these techniques [16, 17] and their technical and cost-related issues [13]. Alternatively, IHC of transducing-like enhancer split 1 (TLE1) has been recognized to distinguish SS from other soft tissue malignancies [3, 18]. Although TLE1 is reported to show strong and diffuse nuclear staining in SS, the specificity of TLE1 IHC for the diagnosis of SS is low because of its positivity in up to one-third of non-SS sarcomas [3, 15, 19–21]. Recently, Baranov et al. evaluated SSX-SS18 IHC in 100 genetically confirmed primary SS tumors and 300 histologic mimics of SS, demonstrating that SS18-SSX IHC had high sensitivity (95%) and high specificity (100%) for the diagnosis of primary SS and described that the test could replace traditional genomic tests based on its technical simplicity and high diagnostic performance [4]. No study investigated the diagnostic performance of the test for the diagnosis of metastatic SS to date and our current study is the first to validate the usefulness of SS18-SSX IHC for the diagnosis of pulmonary metastatic SS, which demonstrated high sensitivity (100%) and sensitivity (100%) to distinguish SS from clinical and histologic mimics.

Our current study also provides supportive evidence to use SS18-SSX IHC for the differential diagnosis of indeterminate mediastinal sarcomas. Because of the rarity of primary mediastinal sarcomas including SS [22], the routine use of genetic tests for the differential diagnosis of SS would not be realistic in clinical practice. In case 2, the definitive diagnosis of SS was not reached until the initial metastasectomy 108 months after the primary surgery when SS was suspected, and FISH was performed. In such cases, SS18-SSX IHC would be a better alternative option for differentiating SS because of its technical simplicity, relatively low cost, and good diagnostic performance.

More importantly, our current study suggests the potential utility of SS18-SSX IHC for biopsy and/or cytology specimens. In case 5, sufficient staining of SS18-SSX was confirmed by needle biopsy and touch imprint cytology specimens from the primary site of SS. Although SS18-SSX IHC in biopsy or cytology specimens from pulmonary metastatic SS was not assessed in this study, a differential diagnosis of SS could be made using small amounts of tumor tissue or cells obtained by bronchoscopy or imaging-guided biopsy.

The five primary and ten metastatic SS samples in this study were strongly positive for SS18-SSX IHC (100% sensitivity). However, due to uncommon variants of SS18-SSX fusion, the sensitivity of SS18-SSX IHC is not perfect [4, 23]. Tahara et al. suggested RT-PCR and DNA sequencing would be useful to confirm the diagnosis in such cases [23]. Baranov et al., however, suggested that these cases could be recognized by the SSX C-terminus antibody (E5A2C) and, therefore, the combination of these IHCs (SS18-SSX and SSX C-terminus) could be the gold standard of molecular genetic or cytogenetic testing in the majority of SS. SSX IHC should be considered in cases with a high suspicion of SS but negative for SS18-SSX.

This study had some limitations. First, the number of SS cases was small, and there were no cases with negative SS18-SSX IHC in the primary site of SS. Therefore, it is unknown whether metastatic sites in such cases could be identified using SS18-SSX IHC. Second, we only tested two selected metastatic sites in each SS case, which might have affected the results of this study. Third, we did not assess SS18-SSX IHC in a primary carcinosarcoma of the lung, which is an important differential diagnosis for SS.

In conclusion, we showed the usefulness of IHC of SS18-SSX fusion-specific antibody for the differential diagnosis of pulmonary metastatic SS from clinical/histological mimics with high diagnostic performance (100% sensitivity and 100% specificity). We also showed the potential utility of SS18-SSX IHC for the diagnosis of SS arising from rare origins such as the mediastinum and SS obtained by biopsy/cytology specimens. This simple and reliable method could replace traditional genomic tests in terms of the differential diagnosis of pulmonary metastatic SS.

Synovial sarcoma (SS)

fluorescence in situ hybridization (FISH)

reverse transcriptase-polymerase chain reaction (RT-PCR)

immunohistochemistry (IHC)

solitary fibrotic tumor (SFT)

bovine serum albumin (BSA)

phosphate-buffered saline (PBS)

Ethical Approval: This study was approved by the Shinshu University Research Ethics Committee (No. 4870).

Consent to Participate /Consent for Publication: All patients in this study consented to their involvement.

Funding: Not Applicable

Competing interests: The authors declare that they have no competing interests.

Availability of data and materials: The data presented in this study can be shared in response to reasonable request to the corresponding author.

Authors’ Contributions: KM, KS, TE, SK, SM, TT, and KH: surgical pulmonary resection, methodology, and data acquisition. KM and TU: evaluation of pathology

Acknowledgements:

We thank Masanobu Momose of the Department of Laboratory Medicine and Sachie Shimoeda of the Division of General Thoracic Surgery at Shinshu University School of Medicine for their technical assistance in immunohistochemistry analysis.

Shi W, Indelicato DJ, Morris CG, Scarborough MT, Gibbs CP, Zlotecki RA. Long-term treatment outcomes for patients with synovial sarcoma: a 40-year experience at the University of Florida. Am J Clin Oncol. 2013;36:83-8.
Sultan I, Rodriguez-Galindo C, Saab R, Yasir S, Casanova M, Ferrari A. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients. Cancer. 2009;115:3537-47.
Thway K, Fisher C. Synovial sarcoma: defining features and diagnostic evolution. Ann Diagn Pathol. 2014;18:369-80.
Baranov E, McBride MJ, Bellizzi AM, Ligon AH, Fletcher CDM, Kadoch C, et al. A novel SS18-SSX fusion-specific antibody for the diagnosis of synovial sarcoma. Am J Surg Pathol. 2020;44:922-33.
Bergh P, Meis-Kindblom JM, Gherlinzoni F, Berlin O, Bacchini P, Bertoni F, et al. Synovial sarcoma: identification of low and high risk groups. Cancer. 1999;85:2596-607.
Stanelle EJ, Christison-Lagay ER, Wolden SL, Meyers PA, La Quaglia MP. Pulmonary metastasectomy in pediatric/adolescent patients with synovial sarcoma: an institutional review. J Pediatr Surg. 2013;48:757-63.
Predina JD, Puc MM, Bergey MR, Sonnad SS, Kucharczuk JC, Staddon A, et al. Improved survival after pulmonary metastasectomy for soft tissue sarcoma. J Thorac Oncol. 2011;6:913-9.
Spillane AJ, A'Hern R, Judson IR, Fisher C, Thomas JM. Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol. 2000;18:3794-803.
Lee K, Kang MC, Lee HW, Park JH, Baek HJ, Cho SJ, et al. Pulmonary metastasectomy in adult patients with synovial sarcoma: A single-center experience. Korean J Thorac Cardiovasc Surg. 2016;49:451-5.
Yamamoto Y, Kanzaki R, Kanou T, Ose N, Funaki S, Shintani Y, et al. Long-term outcomes and prognostic factors of pulmonary metastasectomy for osteosarcoma and soft tissue sarcoma. Int J Clin Oncol. 2019;24:863-70.
dos Santos NR, de Bruijn DR, van Kessel AG. Molecular mechanisms underlying human synovial sarcoma development. Genes Chromosomes Cancer. 2001;30:1-14.
Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002;62:135-40.
Zaborowski M, Vargas AC, Pulvers J, Clarkson A, de Guzman D, Sioson L, et al. When used together SS18-SSX fusion-specific and SSX C-terminus immunohistochemistry are highly specific and sensitive for the diagnosis of synovial sarcoma and can replace FISH or molecular testing in most cases. Histopathology. 77:588-600.
Miettinen M, Limon J, Niezabitowski A, Lasota J. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma. Am J Surg Pathol. 2001;25:610-7.
Kosemehmetoglu K, Vrana JA, Folpe AL. TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms. Mod Pathol. 2009;22:872-8.
Ten Heuvel SE, Hoekstra HJ, Suurmeijer AJ. Diagnostic accuracy of FISH and RT-PCR in 50 routinely processed synovial sarcomas. Appl Immunohistochem Mol Morphol. 2008;16:246-50.
Vargas AC, Selinger C, Satgunaseelan L, Cooper WA, Gupta R, Stalley P, et al. FISH analysis of selected soft tissue tumors: Diagnostic experience in a tertiary center. Asia Pac J Clin Oncol. 2019;15:38-47.
Jagdis A, Rubin BP, Tubbs RR, Pacheco M, Nielsen TO. Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma. Am J Surg Pathol. 2009;33:1743-51.
Valente AL, Tull J, Zhang S. Specificity of TLE1 expression in unclassified high-grade sarcomas for the diagnosis of synovial sarcoma. Appl Immunohistochem Mol Morphol. 2013;21:408-13.
Foo WC, Cruise MW, Wick MR, Hornick JL. Immunohistochemical staining for TLE1 distinguishes synovial sarcoma from histologic mimics. Am J Clin Pathol. 2011;135:839-44.
Matsuyama A, Hisaoka M, Iwasaki M, Iwashita M, Hisanaga S, Hashimoto H. TLE1 expression in malignant mesothelioma. Virchows Arch. 2010;457:577-83.
Hartel PH, Fanburg-Smith JC, Frazier AA, Galvin JR, Lichy JH, Shilo K, et al. Primary pulmonary and mediastinal synovial sarcoma: a clinicopathologic study of 60 cases and comparison with five prior series. Mod Pathol. 2007;20:760-9.
Tahara S, Kohara M, Honma K, Morii E. Detection of synovial sarcoma with an atypical fusion transcript by using SS18-SSX and SSX antibodies. Pathol Int. 2020;70:689-91.

PDF

Editorial decision: Minor Revision
02 May, 2021
Review #3 received at journal
01 May, 2021
Review #2 received at journal
25 Apr, 2021
Reviewer #3 agreed at journal
23 Apr, 2021
Reviewer #2 agreed at journal
11 Apr, 2021
Review #1 received at journal
11 Apr, 2021
Reviewers invited by journal
10 Apr, 2021
Reviewer #1 agreed at journal
10 Apr, 2021
Editor assigned by journal
28 Mar, 2021
Submission checks completed at journal
28 Mar, 2021
Editor invited by journal
28 Mar, 2021
First submitted to journal
25 Mar, 2021

You are reading this latest preprint version

Usefulness of SS18-SSX antibody as a diagnostic marker for pulmonary metastatic synovial sarcoma

Status:

Version 1

Abstract

Background

Methods

Results

Conclusions

Figures

Background

Methods

Study cohort and design

Immunohistochemical staining

Results

Characteristics of patients with synovial sarcoma

Discussion

Conclusion

Abbreviations

Declarations

References

Status:

Version 1